Missed Opportunities Punctuate NICE Reform, Says UK Industry
Executive Summary
ABPI calls on UK to address lower investments in new medicines compared with comparable markets.
You may also be interested in...
Pharma Firms Keep A Close Eye On NICE's New HTA Approach In UK
Companies are keen to know how the disease severity modifier and a more flexible approach to uncertainty will be applied to health technology appraisals for drugs in practice. They also want reassurance that there will be consistency in deliberations by NICE’s various committees and advisory groups.
Australian HTA Consults On Discount Rate
PBAC, Australia’s health technology assessment body, is asking for feedback on whether its discount rate – a tool used in economic modelling – is too high.
NICE Board Approves Landmark Changes To Increase Flexibility Of Drug Evaluation Methods And Processes In England
Big changes are in store at UK health technology assessment body NICE aimed at improving the way medicines are assessed.